Tegsedi

Active Ingredient(s): Inotersen Sodium
FDA Approved: * October 5, 2018
Pharm Company: * AKCEA THERAPS
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tegsedi Overview

Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain.[3] It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, includin...

Read more Tegsedi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Polyneuropathy

Recent Tegsedi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Tegsedi: (1 result)

Sorted by National Drug Code

• 72126-007 Tegsedi 284 mg/1.5ml Subcutaneous Injection, Solution by Akcea Therapeutics, Inc.

Other drugs which contain Inotersen Sodium or a similar ingredient: (1 result)

• INOTERSEN SODIUM